Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Revealed
India's Third Giant Leap

This Could be One of the Biggest Opportunities for Investors




Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster
covering exciting investing ideas and opportunities in India.

AD

Markets Trade Near the Dotted Line
Thu, 24 Dec 11:30 am

After opening the day on a flattish note, the Indian Markets continue continued to trade near the dotted line. Sectoral indices are trading on a mixed note with stocks from the capital goods and metal sectors leading the gains. Consumer durables stocks are trading in the red.

The BSE Sensex is trading down by 8 points (0.03%) and the NSE Nifty is trading down by 5 points (0.1%). The BSE Mid Cap index and the BSE Small Cap index are trading positively, up by 0.3% and 0.5% respectively. The rupee is trading at 65.94 to the US$.

Most of the stocks in the healthcare space are trading on a positive note with Biocon Ltd and Aurobindo Pharma witnessing maximum buying interest. As per an article in The Economic Times, the Health Ministry has drawn up the revised National List of Essential Medicines. The Indian government has accepted the national list of essential medicines as a key instrument in balanced healthcare delivery system. The list includes accessible, affordable and quality medicine at the primary, secondary and tertiary levels of healthcare.

The number of medicines under the same has gone up to 376 from 348 in the earlier list prepared in 2011. There are new additions as well as some deletions in the new list. Overall the number of therapeutic areas has gone up marginally from 27 to 29. Further, the span of price control may seem higher as the new list has a few drugs that generate higher prescriptions. To know more about the impact of drug price control on pharma sector, please click here.

Power stocks are trading on a mixed note with Reliance Infra leading the gains and KSK Energy leading the losses. As per a leading financial daily, the government is planning to seal a contract with Westinghouse Electric Co LLC to build six nuclear reactors in the first half during the next year. This comes as the government's US$ 150 billion dollar nuclear power programme is getting off the ground.

The proposed power plant, which is going to be set up in Gujarat, will accelerate India's plan to build roughly 60 reactors. The same would record as the world's second-biggest nuclear energy market after China. The construction of the roughly 1,100 MW (mega watt) reactors is said to be initiated later in

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets Trade Near the Dotted Line". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited).

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Research Private Limited (formerly Equitymaster Agora Research Private Limited) (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.